EMBLAVEO, in combination with metronidazole, is indicated in patients 18 years and older who have limited or no alternative treatment options for the treatment of complicated intra-abdominal ...

Emblaveo targets cIAI caused by Gram-negative microorganisms, including Escherichia coli and Klebsiella pneumoniae. The ...

Emblaveo is supplied in a single-dose vial as a lyophilized powder containing 1.5g of aztreonam and 0.5g of avibactam that requires reconstitution and dilution prior to IV infusion.

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Feb. 10, 2025 -- The FDA has approved a new antibiotic combination called Emblaveo to treat serious infections of the abdomen in adults who have few or no other treatment options. It will be given ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused ...

Emblaveo is supplied in a single-dose vial as a lyophilized powder containing 1.5g of aztreonam and 0.5g of avibactam that requires reconstitution and dilution prior to IV infusion.

Emblaveo (aztreonam and avibactam), is the first monobactam antiobiotic andbeta-lactamase inhibitor combination approved for this condition, according to a press release from AbbVie.